The local literature lacks comprehensive information regarding the actual incidence of intrauterine growth restriction (IUGR) and oligohydramnios and currently available therapeutic options. Therefore, the current study was planned with the objective to evaluate the impact of enoxaparin therapy compared with standard management on neonatal outcomes in pregnancies complicated by intrauterine growth restriction (IUGR) with oligohydramnios.
Women aged 18-40 years
Singleton pregnancy
Gestational age ≥28 weeks (confirmed by first-trimester scan or reliable last menstrual period)
Diagnosed with both IUGR and oligohydramnios
Multiple gestation
Major fetal congenital anomalies
Maternal medical disorders affecting pregnancy outcome (e.g., uncontrolled diabetes, chronic hypertension, renal disease)
Known coagulation disorders or contraindications to enoxaparin
Muhammad Aamir Latif
Lead sponsor
RESnTEC, Institute of Research
Sponsor institution